Bristol Myers: positive data for lung cancer

(CercleFinance.com) - Bristol Myers Squibb announces that its phase III trial CheckMate -816 to evaluate Opdivo (nivolumab), has attained its primary endpoint of pathologic complete response in non-small cell lung cancer (NSCLC).


The pharmaceutical laboratory specifies that “significantly more patients treated with Opdivo (nivolumab) plus chemotherapy before surgery showed no evidence of cancer cells in their resected tissue compared to those treated with chemotherapy alone”.

It underlines that “Opdivo-based treatments have now shown benefit in four Phase 3 clinical trials in early-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma”.

Copyright (c) 2020 CercleFinance.com. All rights reserved.